Dental considerations in patients with liver disease by Cruz Pamplona, Marta et al.
e127
J Clin Exp Dent. 2011;3(2):e127-34.                                                        Dental treatment in patients with liver disease.
Journal section:    Oral Medicine and Pathology                                                             doi:10.4317/jced.3.e127
Publication Types: Review
Dental considerations in patients with liver disease
 
Marta Cruz-Pamplona 1, María Margaix-Muñoz 1, Maria Gracia Sarrión-Pérez 1
1 Degree in Dentistry. Master in Oral Medicine and Surgery. Faculty of Medicine and Dentistry. University of Valencia. Spain.
Correspondence:
Av/ Gaspar Aguilar 81-13
46017 Valencia, Spain
Phone: 630166697
E-mail: martacruzp@hotmail.com
Received: 23/06/2010
Accepted: 16/01/2011
Abstract 
Introduction: Liver diseases are very common, and the main underlying causes are viral infections, alcohol abuse 
and lipid and carbohydrate metabolic disorders. The liver has a broad range of functions in maintaining homeos-
tasis and health, and moreover metabolizes many drug substances. Objective: An update is provided on the oral 
manifestations seen in patients with viral hepatitis, alcoholic and non-alcoholic liver disease, cirrhosis and hepa-
tocellular carcinoma, and on the dental management of such patients. Material and methods: A Medline-PubMed 
search was conducted of the literature over the last 15 years using the keywords: “hepatitis”, “alcoholic hepatitis”, 
“fatty liver”, “cirrhosis” and “hepatocellular carcinoma”. A total of 28 articles were reviewed, comprising 20 lite-
rature reviews, a clinical guide, three clinical trials and four case series. Results: Oral clinical manifestations can 
be observed reflecting liver dysfunction, such as bleeding disorders, jaundice, foetor hepaticus, cheilitis, smooth 
tongue, xerostomia, bruxism and crusted perioral rash. In the case of infection caused by hepatitis C virus (HCV), 
the most frequent extrahepatic manifestations mostly affect the oral region in the form of lichen planus, xerostomia, 
Sjögren’s syndrome and sialadenitis. The main complications of the patient with liver disease are risk of contagion 
(for healthcare personnel and other patients), the risk of bleeding and the risk of toxicity due to alteration of the 
metabolism of certain drugs.
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Introduction 
Liver diseases are very common and can be classified 
as acute (characterized by rapid resolution and complete 
restitution of organ structure and function once the un-
derlying cause has been eliminated) or chronic (charac-
terized by persistent damage, with progressively impai-
red organ function secondary to the increase in liver cell 
damage). Based on the extent and origin of the damage, 
chronic liver disease ranges from steatosis or fatty liver 
to hepatocellular carcinoma, and includes hepatitis, fi-
brosis and cirrhosis. Liver diseases can also be classified 
as infectious (hepatitis A, B, C, D and E viruses, infec-
tious mononucleosis, or secondary syphilis and tubercu-
losis) or non-infectious (substance abuse such as alcohol 
and drugs, e.g., paracetamol, halothane, ketoconazole, 
methyldopa and methotrexate) (1).
The liver has a broad range of functions in maintaining 
homeostasis and health: it synthesizes most essential 
serum proteins (albumin, transporter proteins, blood 
coagulation factors V, VII, IX and X, prothrombin and 
fibrinogen (1), as well as many hormone and growth 
factors), produces bile and its transporters (bile acids, 
cholesterol, lecithin, phospholipids), intervenes in the 
regulation of nutrients (glucose, glycogen, lipids, cho-
lesterol, amino acids), and metabolizes and conjugates 
lipophilic compounds (bilirubin, cations, drugs) to faci-
litate their excretion in bile or urine. Liver dysfunction 
alters the metabolism of carbohydrates, lipids, proteins, 
drugs, bilirubin and hormones (2). Accordingly, liver di-
sease is characterized by a series of aspects that must be 
taken into account in the context of medical and dental 
care (3).
Since many drug substances are metabolized in the liver, 
it is essential for the clinician to compile a complete me-
dical history, evaluating all body systems and the medi-
cation used by the patient. The patient drug metabolizing 
capacity can be evaluated based on the analysis of enzy-
mes such as alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST), and other liver function tests 
(2, 4).
In situations of advanced liver disease, the vitamin K le-
vels can be significantly lowered, thus giving rise to a re-
duction in the production of blood coagulation factors. In 
addition, portal hypertension can scavenge platelets for-
med in the spleen, thus giving rise to thrombocytopenia. 
This in turn can lead to an excessive bleeding tendency, 
which is one of the main adverse effects seen during the 
treatment of patients with impaired liver function (4).
Dentists are particularly at risk of hepatitis B and C con-
tagion, due to the transmission routes of these viruses, 
since these professionals are exposed to the blood and 
oral secretions of potentially infected individuals (5) – 
particularly in the case of accidents with sharp or cutting 
instruments.
VIRAL HEPATITIS
Hepatitis of viral origin comprises a heterogeneous 
group of diseases caused by at least 6 different types of 
viruses: A, B, C, D, E and G (2). 
Five million new cases of viral hepatitis are documented 
each year throughout the world, and a study published 
by Chandler-Gutiérrez et al. (6) estimates the prevalence 
in Spain to be 3.7%.
- Hepatitis A
Hepatitis A is caused by the hepatitis A virus (HAV), 
an RNA picornavirus (3) endemic in many developing 
countries. Its estimated prevalence is 1.1% (6). This vi-
rus is transmitted via the enteral (oral-fecal) route (5), as 
a result of the ingestion of contaminated water or food 
(mollusks), though intrafamilial contagion has also been 
described, as well as contagion in closed institutions and 
secondary to sexual intercourse.
The disease is typically mild and self-limiting, and is cha-
racterized by the sudden onset of nonspecific symptoms. 
There is no carrier state. In children or young indivi-
duals the disease tends to be asymptomatic, while adults 
typically present fever, fatigue, abdominal discomfort, 
diarrhea, nausea and/or jaundice. The patient is able to 
transmit the infection during the incubation period (2-6 
weeks) and until the appearance of symptoms.
The diagnosis is based on the signs and symptoms and 
on serological testing for anti-HAV IgM and IgG anti-
bodies (3). Host response in the form of anti-HAV anti-
bodies affords lifelong immunity, protecting the patient 
against future HAV infection. 
The risk of nosocomial contagion among healthcare per-
sonnel is quite low (3). Vaccines are available that offer 
immunity against HAV (Havrix®, Vaqta®) for people 
at risk (i.e., subjects traveling to endemic areas, drug 
abusers, patients with chronic liver disease and subjects 
with occupational risk factors) (2, 3).
- Hepatitis B
The hepatitis B virus (HBV) is an encapsulated DNA 
virus that replicates within the hepatocyte (3). Hepatitis 
B is a worldwide health problem, with an estimated 400 
million carriers of the virus (5). It has been calculated 
that 1.53% of all patients reporting to the dental clinic 
are HBV carriers (6).
The transmission routes comprise sexual contact, intra-
venous drug use and blood transfusions. In Asia perinatal 
transmission is common (3). An important consideration 
among dental professionals is the risk of percutaneous 
transmission through punctures or cuts with instruments 
infected from HBV-positive patients, or absorption 
through the mucosal surfaces (eyes, oral cavity). Trans-
mission through saliva can occur as a result of absorp-
tion from mucosal surfaces (2). Some studies have re-
ported the presence of HBsAg in saliva and crevicular 
fluid of HBV-positive patients. Dental professionals, 
particularly those dedicated to oral surgery (7), have a 
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symptoms are observed, these tend to be mild, and most 
subjects remain relatively asymptomatic during the first 
two decades after infection with the virus (4).
The morbidity associated to HCV infection is due not 
only to the consequences of chronic liver disease but 
also to the extrahepatic manifestations (11). The best 
documented condition associated to hepatitis C is cryo-
glubulinemia, a multisystemic disorder often characte-
rized by purpura, weakness and joint pain, and which 
may precede the development of B-cell non-Hodgkin 
lymphoma or membrane proliferative glomerulonephri-
tis (12). Other related disorders are porphyria cutanea 
tarda, lichen planus, sialadenitis, thyroid gland dys-
function, diabetes mellitus and peripheral neuropathy 
(11). Over 74% of all HCV-infected patients ultimately 
develop extrahepatic manifestations in the course of the 
infection (10).
Different enzyme-linked immunosorbent assay (ELISA) 
and recombinant immunoblot assay (RIBA) techniques 
have been developed for the diagnosis of HCV infection, 
though the diagnostic gold standard remains detection 
of the viral genome using real time polymerase chain 
reaction (RT-PCR) technology (3, 12).
No effective vaccine against HCV has yet been deve-
loped, and spontaneous resolution is unusual (12). The 
existing therapy comprises combination treatment with 
interferon and ribavirin, which offers a sustained res-
ponse rate of 30-40% (3).
CHRONIC HEPATITIS
Chronic hepatitis is a diffuse inflammatory disorder of 
the liver with a duration of over 6 months in which the 
underlying cause can be infectious (mainly hepatitis C 
virus and, to a lesser extent, hepatitis B and D viruses), 
pharmacological or immunological.
The disease can develop in the absence of symptoms or 
with nonspecific manifestations such as fatigue, nausea 
or abdominal pain. The course is normally slow and pro-
gressive, and symptoms typically do not manifest until 
years after the initial causal event (e.g., infection). Some 
patients develop the disorder without significant liver 
damage, while others rapidly progress towards cirrhosis 
and possible hepatocarcinoma. Chronic hepatitis due to 
HCV infection is the principal cause of cirrhosis and he-
patocellular carcinoma (3).
ALCOHOLIC LIVER DISEASE
Alcoholic liver disease is one of the 10 most common 
causes of death in the industrialized world, and is res-
ponsible for 3% of all fatalities. The epidemiological 
data indicate a threshold of 80 g of alcohol in males and 
20 g in females, consumed on a daily basis during 10-12 
years, in order to cause the corresponding liver damage. 
Ten grams of pure ethanol are equivalent to a glass of 
wine or a beer, while a glass of whiskey doubles that 
amount. Factors such as chronic hepatitis C infection, 
obesity and genetic factors can accelerate the develop-
three- to four-fold greater risk of HBV infection than 
the general population (3), though vaccines and barrier 
methods have contributed to lessen the risk (2, 7). Fo-
llowing inoculation, the seroconversion risk is 30% (8). 
The incubation period lasts 2-6 months. Over 50% of 
all infections are subclinical and are not associated with 
jaundice. In this context, since the disease may prove 
asymptomatic, many people are unaware that they have 
suffered the infection in the past (5). Approximately 
90% of all HBV-infected adults show complete healing, 
but 5-10% develop chronic hepatitis with complications 
in the form of cirrhosis and hepatocellular carcinoma (3, 
4), resulting in 5000-6000 deaths a year due to liver fa-
ilure (4).
The disease is diagnosed by quantifying the levels of 
HBV DNA, HBsAg and the antigen / antibody ratio.
Vaccines have been developed that induce an effective 
immune response against the virus in most patients. If 
a non-immunized individual becomes exposed to HBV, 
immunoglobulin can be administered to afford protec-
tion after exposure. The current management protocols 
include HBV immunization as part of the pediatric vac-
cination program (3).
- Hepatitis C
Hepatitis C virus (HCV) infection is the main cause of 
chronic liver disease (9, 10) and of liver-related morbi-
dity and mortality worldwide (9). It has been estimated 
that 8000 to 10,000 deaths a year are attributable to HCV 
(4), and the latter represents the main indication for li-
ver transplantation in Europe and the United States (9). 
The estimated global prevalence of the disease is 2.2%, 
representing approximately 130 million infected indivi-
duals in the world (10). Great geographical variability 
is observed (9), possibly as a result of immunogenetic 
factors. The lowest prevalences are found in the Uni-
ted Kingdom and Scandinavia, and the highest in Egypt 
(11).
HCV is an RNA virus mainly transmitted via the paren-
teral route from infected blood (3, 9, 12). The sources of 
contagion include blood transfusion (although the risk 
has been minimized since donor blood tests and controls 
are made (12)), percutaneous exposure through contami-
nated instruments, and occupational exposure to blood 
(9). The individuals at greatest risk are hemophiliacs, 
patients on dialysis and parenteral drug abusers. Other 
transmission routes are sexual contact and perinatal and 
idiopathic contagion (3). The prevalence of the infection 
among dental professionals is similar to that found in 
the general population, though epidemiological studies 
suggest that dentists constitute a risk group for HCV in-
fection (12).
Following inoculation, the estimated seroconversion 
risk is 1.8% (8). The incubation period is long (up to 
three months), and 85% of all patients with HCV in-
fection develop chronic hepatitis. In those cases where 
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ment of alcoholic liver disease even with smaller doses 
of alcohol.
Alcoholism is characterized by physical dependency 
that includes great tolerance of large amounts of alcohol 
in blood, a strong urge to drink, difficulty controlling 
consumption (13), progressive abandonment of usual 
daily life activities, and persistence of the habit despite 
its consequences. Alcoholism in turn leads to malnutri-
tion, anemias, diminished immune function and impor-
tant drug interactions.
The clinical spectrum of alcoholic liver disease ranges 
from simple liver steatosis (fatty liver) with alcoholic 
(toxic) hepatitis to more severe steatohepatitis or cirrho-
sis. Simple steatosis is the most common presentation, 
is found in 90% of all heavy drinkers, and proves rever-
sible upon abandoning the habit. Alcoholic hepatitis is 
observed in over 35% of all heavy drinkers and tends to 
be a precursor of cirrhosis. The condition ranges from 
asymptomatic forms to liver failure and life-threatening 
situations, and is usually accompanied by febricula, 
jaundice, leukocytosis and liver enzyme elevations.
NON-ALCOHOLIC FATTY LIVER
Non-alcoholic fatty liver is defined as the accumulation 
of fat (mainly triglycerides) in the liver, representing 
over 5% of the weight of the organ (5), in the absence of 
alcohol consumption in excess of 10 g a day (15).
The observed liver damage ranges greatly from simple 
steatosis (accumulation of fat in the liver) to steatohepa-
titis (fat accumulation with added inflammation), advan-
ced fibrosis and cirrhosis (16). 
This disorder is mainly associated to obesity, diabetes, 
hyperlipidemia and insulin resistance. There is a strong 
correlation between insulin resistance and excessive 
triglyceride accumulation within the liver cells (15). 
However, 16.4% of all patients with non-alcoholic fatty 
liver present none of these predisposing factors (17). 
The condition is potentially reversible after eliminating 
or minimizing the aforementioned causal factors (14).
No clear treatments have been established to date for 
non-alcoholic fatty liver, though interventions such as 
bariatric surgery (in the case of obese individuals) and 
oral antidiabetic drugs (glitazones) in patients with type 
2 diabetes have shown encouraging results (15).
CIRRHOSIS
Liver cirrhosis is very common in our setting, with well 
defined morphopathological characteristics that lead 
to destruction of the liver parenchyma. The disease is 
accompanied by a series of extrahepatic manifestations 
in other body organs and system (18). Liver cirrhosis 
is irreversible, and is characterized by the formation of 
fibrous scarring in the liver, with the formation of rege-
neration nodules that increase resistance to blood flow 
through the organ. The resulting deficient liver perfu-
sion damages vital structures in the organ and adversely 
affects its physiological functions (19). The main cau-
ses of liver cirrhosis are hepatitis B and C infection and 
alcohol abuse. Other potential causes are non-alcoholic 
steatohepatitis, genetic alterations and autoimmune di-
sorders (3).
The main complications of cirrhosis are portal hyperten-
sion, hepatocellular carcinoma and organ function loss. 
Cirrhosis in itself constitutes a risk factor for the develo-
pment of hepatocellular carcinoma (16).
The treatment options comprise suppression of the cau-
sal stimulus, antiviral therapy and liver transplantation 
in the end stages of cirrhotic disease (3).
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma is the fifth most frequent can-
cer worldwide (16). As such, it constitutes an important 
public health problem, and is one of the most common 
and life-threatening malignancies in the world – with a 
survival rate after two years of only about 2% (3).
It has been estimated that HBV and HCV are responsible 
for over 80% of all hepatocarcinomas. The other cau-
ses are alcoholic and non-alcoholic steatohepatitis. Most 
patients with hepatocellular carcinoma have a history of 
cirrhosis, which in itself constitutes a preneoplastic con-
dition (12, 16).
Liver cirrhosis has a prolonged natural course, and pro-
duces symptoms only in the advanced stages of the di-
sease, when no healing treatment options are available. 
The main treatment for hepatocellular carcinoma is sur-
gery (in those cases where the tumor proves resectable), 
though unfortunately many cases are non-operable due 
to the proximity of vital structures, the presence of me-
tastases, or other comorbidities (3).
Objectives
The present study offers a literature review of the oral 
manifestations that can be found in patients with viral 
hepatitis, alcoholic and non-alcoholic liver disease, cirr-
hosis and hepatocellular carcinoma, and the dental ma-
nagement of patients with these liver disorders.
Material and Methods
A literature search was made of the articles indexed in 
the PubMed – Medline database, using the following 
MeSH validated key words: hepatitis, alcoholic hepati-
tis, fatty liver, cirrhosis and hepatocellular carcinoma. 
The search was limited to articles in English or Spanish 
published over the last 15 years. A total of 28 articles 
were reviewed, comprising 20 literature reviews, a clini-
cal guide, three clinical trials and four case series.
Results
1. ORAL CLINICAL MANIFESTATIONS
The oral cavity can reflect liver dysfunction in the form 
of mucosal membrane jaundice, bleeding disorders, pe-
techiae, increased vulnerability to bruising, gingivitis, 
gingival bleeding (even in response to minimum trau-
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ma) (3, 19), foetor hepaticus (a characteristic odor of 
advanced liver disease), cheilitis, smooth and atrophic 
tongue, xerostomia, bruxism and crusted perioral rash 
(1). In these patients, chronic periodontal disease is a 
common finding. 
Patients with alcoholic hepatitis can present glossitis, 
angle cheilitis and gingivitis, particularly in combination 
with nutritional deficiencies (3, 20). Some patients who 
consume large amounts of alcohol for prolonged periods 
of time can develop sialadenosis. As commented by Frie-
dlander (20), this is believed to be the result of ethanol-
induced peripheral autonomic neuropathy giving rise to 
alterations in salivary metabolism and secretion.
Patients with advanced cirrhosis tend to present defi-
cient oral hygiene, particularly in those cases where the 
liver impairment is associated to alcohol abuse. Bagán et 
al. (18) reported worsened dental conditions in patients 
with liver cirrhosis, in coincidence with other authors 
such as Novacek et al. (21), who considered that due to 
the severity and characteristics of cirrhosis, patients tend 
to neglect care of the oral cavity (18).
In a recent study, Grossmann et al (9). found many pa-
tients with HCV infection to present poor dental health – 
a situation that contributes to worsen their quality of life. 
Extrahepatic manifestations have been reported in 74% 
of all HCV-infected individuals (19), and some of these 
conditions predominantly or exclusively affect the oral 
region (10). The main disorders associated with HCV 
infection are xerostomia, Sjögren’s syndrome (SS), sia-
ladenitis and particularly lichen planus (LP) (9).
Xerostomia increases patient vulnerability to caries and 
oral soft tissue disorders (9) which, in combination with 
deficient hygiene, in turn facilitate the development of 
candidiasis.
It has not yet been demonstrated whether HCV infection 
causes disease similar to primary Sjögren’s syndrome 
or whether it is directly responsible for development of 
Sjögren’s syndrome in certain types of patients. Howe-
ver, it is notorious that some subjects can present a triple 
association of HCV infection, Sjögren’s syndrome and 
sialadenitis or salivary gland lymphoma (10).
Although bacteria are the main cause of sialadenitis, vi-
ruses such as HCV have been implicated as causes of 
sialadenitis associated to xerostomia (19).
Epidemiological evidence suggests that lichen planus 
may be significantly associated to HCV infection, though 
the existing data are controversial (22). This association 
appears to be dependent upon the geographical setting, 
being more common in Mediterranean countries and in 
Japan (22). Bagán et al. (23) found the prevalence of 
HCV infection to be greater in patients with oral lichen 
planus (OLP) than in the control group. Although further 
studies are needed, recent data suggest that patients are 
most likely first infected with HCV and posteriorly de-
velop lichen planus (24) – though the way in which this 
occurs is not known.
2. DENTAL MANAGEMENT
Liver disease has important implications for patients 
receiving dental treatment (3). The most frequent pro-
blems associated with liver disease in clinical practice 
refer to the risk of viral contagion on the part of the den-
tal professionals and rest of patients (cross-infection), 
the risk of bleeding in patients with serious liver disease, 
and alterations in the metabolism of certain drug subs-
tances (1) – which increases the risk of toxicity.
HCV has been detected on different surfaces within the 
dental clinic after treating patients with hepatitis C, and 
the virus moreover is able to remain stable at room tem-
perature for over 5 days (12). Strict sterilization mea-
sures are therefore required, since deficient sterilization 
can expose both the dentist and other patients to hepa-
titis infection (5). The universal protective measures are 
applicable in order to prevent cross-infection, i.e., the 
use of barrier methods, with correct sterilization and di-
sinfection measures (1). It has been demonstrated that 
conventional sterilization techniques eliminate specific 
proteins and nucleic acids (HBV DNA and HCV RNA) 
from dental instruments previously infected with HBV 
and HCV. Although there are no data confirming their 
efficacy in lessening the risk of contagion, the measures 
recommended in the case of accidental perforation of the 
skin with instruments or needles comprise careful was-
hing of the wound (without rubbing, as this may inocula-
te the virus into deeper tissues) for several minutes with 
soap and water, or using a disinfectant of established 
efficacy against the virus (iodine solutions or chlorine 
formulations). In turn, pressure should be applied benea-
th the level of the wound in order to induce bleeding 
and thus help evacuate any possible infectious material. 
If exposure through some mucosal membrane has oc-
curred, abundant irrigation with tap water, sterile saline 
solution or sterile water is advised, for several minutes. 
The rationale behind these measures is to reduce the 
number of viral units to below the threshold count nee-
ded to cause infection (i.e., the infectious dose). In this 
sense, dilution with water may lower the viral count to 
below this threshold (8). Whenever possible, the hepa-
titis antigen status of the patient should be determined. 
In the event of parenteral exposure to hepatitis virus-
positive antigens, the dentist should receive treatment 
with anti-hepatitis B immunoglobulin (5). Table 1 offers 
a schematic description of the steps to be followed.
The compilation of a detailed clinical history is essen-
tial before dental treatment in order to identify patients 
posing possible risks (5), together with a thorough oral 
exploration. Interconsultation with the patient physician 
or specialist is advisable in order to establish a safe and 
adequate treatment plan adapted to the medical condi-
tion of the patient (3), considering the degree of liver 
functional impairment involved (1). Exploration of the 
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oral cavity should assess any signs alerting to the exis-
tence of systemic disease. The patient should receive an 
explanation of the risks associated with treatment, and 
informed consent is to be obtained.
In patients with acute-phase viral hepatitis, only emer-
gency treatment should be considered. In subjects with 
chronic hepatitis it is important to determine the pos-
sible existence of associated disorders (autoimmune 
processes, diabetes, etc.) in order to prevent their direct 
complications and problems derived from specific me-
dication use (corticosteroids and/or immune suppres-
sors). Evaluation is also required of the possible medical 
conditions associated to HCV contagion, fundamentally 
blood transmitted infections (HIV, HBV).
It also must be taken into account that liver disease is 
often associated with a decrease in plasma coagulation 
factor concentrations (2, 3). In a patient with liver di-
sease, the surgical risk is related to the severity of the 
disease, the type of surgery planned, and the presence 
of comorbidities. Surgery is contraindicated in patients 
with certain conditions such as acute hepatitis, acute li-
ver failure or alcoholic hepatitis (25). If invasive mea-
sures are required, prior coagulation and hemostasis 
tests are required: complete blood count, bleeding time, 
prothrombin time / international normalized ratio (INR), 
thrombin time, thromboplastin time and liver bioche-
mistry (GOT, GPT and GGT) (1, 26). Table 2 reports 
the normal coagulation test values. In the event altered 
test values are detected, the hematologist or liver spe-
cialist should be consulted (3), with the postponement 
of elective treatment. Any emergency treatments should 
be provided in the hospital setting (4). In the event of 
surgery, trauma should be minimized (3) in order to 
optimize hemostasis, with a careful surgical technique, 
applying pressure to control bleeding and using hemos-
tatic agents (2). Based on the laboratory test findings and 
the treatment to be carried out, local hemostatic agents 
may be advisable (oxidized and regenerated cellulose), 
as well as antifibrinolytic agents (tranexamic acid), fresh 
plasma, platelets and vitamin K (1, 26). Antibiotic pro-
phylaxis is suggested, since liver dysfunction is associa-
ted to diminished immune competence (2).
Liver disease may result in alterations in the metabolism 
of certain drugs. The physician treating the patient the-
refore should be consulted in order to establish which 
drugs are used, their doses and possible interactions 
(3). The administration of certain analgesics, antibiotics 
and local anesthetics is generally well tolerated by pa-
tients with mild to moderate liver dysfunction, though 
modifications may prove necessary in individuals with 
advanced stage liver disease (2). In this context, drugs 
metabolized in the liver may have to be used with cau-
PROCeDuRe AfteR ACCIDentAl InjuRy
Puncture/Cut Mucosal surface contact
1. Careful washing of the wound, without rubbing, for several 
minutes with soap and water or a disinfectant. Abundant irrigation with water or saline solution 
for several minutes.2. Pressure applied beneath the level of the wound to induce 
bleeding.
Determine the hepatitis antigen status of the patient 
Parenteral exposure to hepatitis virus-positive antigens  anti-hepatitis B immunoglobulin 
Table 1. Procedure to be followed after accidental exposure to infected blood.
test normal values
Bleeding time 1-3 minutes
Prothrombin time 11-15 seconds
Thrombin time 15-20 seconds
Thromboplastin time 25-35 seconds
Platelet count 150.000-400.000/mm3< 50.000/mm3: bleeding
INR 0,9-1,1
Table 2. Normal coagulation test values.
Drugs metabolized mainly in the liver
Local anesthetics
Lidocaine
Prilocaine
Mepivacaine
Bupivacaine
Analgesics
Aspirin
Acetaminophen (Paracetamol)
Ibuprofen
Codeine
Meperidine
Sedatives
Diazepam
Barbiturates
Antibiotics
Erythromycin
Clindamycin
Tetracycline
Antifungals
Ketoconazole
Fluconazole
Table 3. Drugs metabolized mainly in the liver (3).
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tion or their doses reduced (1, 26) (Table 3), and certain 
substances such as erythromycin, metronidazole or te-
tracyclines must be avoided entirely (3). Most of the an-
tibiotics prescribed for oral and maxillofacial infections 
can be used in patients with chronic liver disease, and 
in general the beta-lactams can be administered. Amino-
glycosides can increase the risk of liver toxicity in pa-
tients with liver disease, and so should be avoided. The 
metabolism of clindamycin in turn is prolonged in such 
patients, and different studies suggest that it contribu-
tes to liver degeneration (27). Nonsteroidal antiinflam-
matory drugs (NSAIDs) should be used with caution or 
avoided, due to the risk of gastrointestinal bleeding and 
gastritis usually associated to liver disease. Prophylaxis 
can be provided in the form of antacids or histamine re-
ceptor antagonists (2, 3). Acetaminophen (paracetamol) 
is to be avoided in patients with serious liver disease (4), 
and aspirin and NSAIDs are not indicated in patients 
with altered hemostasis (4). Authors such as Douglas et 
al. (27) describe acetaminophen as a safe alternative to 
aspirin or NSAIDs that can be administered at doses of 
up to 4 g/day during two weeks without adverse liver 
effects, warning patients to avoid alcohol consumption 
while receiving treatment with the drug. In patients 
using benzodiazepines, the dose should be lowered, with 
prolongation of the interval between doses. Local anes-
thetics are generally safe provided the total dosage does 
not exceed 7 mg/kg, combined with epinephrine (27). 
Table 4 shows the drugs that are contraindicated and 
those that can be used with caution. Although some of 
these substances are metabolized in the liver, the doses 
at which they are used in dental practice are considered 
to be acceptable – unless the patient suffers very severe 
liver dysfunction.
Patients with alcoholic cirrhosis show increased toleran-
ce of anesthetics, sedatives and hypnotic agents; as a re-
sult, the anesthesia doses should be increased. The safety 
and efficacy of many drug substances are influenced by 
concomitant alcohol consumption. Concern is greatest 
regarding the effects of combining alcohol and central 
nervous system depressors, and the complex effects of 
alcohol upon the capacity of the liver to metabolize drug 
substances (20). Paracetamol combined with alcohol can 
prove particularly dangerous, since the metabolism of 
both substances involves the same enzyme (isoenzyme 
CYP2E1 of the P-450 cytochrome system) (28), and 
care is required not to prescribe alcohol-containing rin-
ses among patients recovering from alcohol abuse (1).
Lastly, preventive oral hygiene measures are indicated 
to lessen the need for dental surgical treatments (12).
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